Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced

• US 8,563,232 B2
• Filed: 10/28/2003
• Issued: 10/22/2013
• Est. Priority Date: 09/12/2000
• Status: Active Grant

• Current Assignee: LifeNet Health, Inc.
• Original Assignee: LifeNet Health, Inc.
• Inventors: Wolfinbarger, Lloyd Jr., Lange, Perry, Moore, Eric, Nolf, Barry, Linthurst-Jones, Alyce
• Primary Examiner(s): FORD, ALLISON M
• Application Number:
  US10/694,190
• Publication Number:
  US 20040067582A1
• Time in Patent Office: 3,647 Days
• Field of Search: None
• US Class Current: 435/1.1
• CPC Class Codes: A01N 1/00 Preservation of bodies of humans or animals, or parts thereof
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
• CPC Class Codes: A01N 1/0247 for perfusion, i.e. for circulating fluid through organs, blood vessels or other living parts
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3683 subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
• CPC Class Codes: A61L 27/3691 characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 5/00 Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; plant reproduction by tissue culture techniques A01H4/00

Abstract

The invention provides methodologies and apparatus for producing devitalized soft-tissue implants where the implant retains metabolically non-viable and/or reproductively non-viable cells, and preferably retains large molecular weight cytoplasmic proteins, such implants produced both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. A devitalized graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, optionally followed by inducing a pressure mediated flow of a salt solution, then washing the tissue to produce the devitalized graft. The devitalized grafts produced are uniform and non-immunogenic. The inventive method allows for the production of multiple devitalized soft tissue implants, where processing time is significantly less than prior art processes and the number of implants produced per day is increased over prior art processes. In clinical use, the devitalized grafts produced exhibit significantly improved in long-term durability and function, and enhanced recellularization post-implantation.

Claims

1. A process for preparing a devitalized soft tissue graft for implantation into a mammalian system, comprising:

extracting a soft tissue sample with an extracting solution comprising a non-denaturing anionic detergent and a first decontaminating agent to produce an extracted tissue comprising cell lysis remnants;

washing at least some cell lysis remnants from said extracted tissue with water and, subsequently placing the extracted, washed tissue into a storage solution comprising a water replacement agent to produce said devitalized soft tissue graft;

wherein said devitalized soft tissue graft retains at least one of non-viable cells or cellular elements capable of inducing graft repopulation with an appropriate cell type, and

wherein said process does not include deoxycholic acid or cholic acid.

2. The process of claim 1, wherein said step of extracting is carried out for a time period of from about 6 hours to about 40 hours.

3. The process of claim 2, wherein said time period is from about 16 to about 24 hours.

4. The process of claim 1, wherein said step of extracting is carried out at a temperature of from about 4°

C. to about 42°

C.

5. The process of claim 4, wherein said temperature is from about 15°

C. to about 27°

C.

6. The process of claim 1, wherein said decontaminating agent is selected from the group consisting of alcohol, chlorine dioxide, polyethyleneimine, glycerol, methylparaben, antibiotic, antimicrobial agent, and a combination thereof.

7. The process of claim 1, wherein said decontaminating agent is selected from the group consisting of ethanol, isopropanol, methanol, glycerol, adonitol, sorbitol, ribitol, galactitol, D-galactose, 1,3 dihydroxypropanol, ethylene glycol, triethylene glycol, propylene glycol, glucose, sucrose, mannitol, xylitol, meso-erythritol, adipic acid, proline, hydroxyproline, and a combination thereof.

13. The process of claim 1 or 8, wherein said process does not include a denaturing detergent.

14. The process of claim 1 or 8, wherein the non-denaturing anionic detergent is N-lauroyl sarcosinate, taurocholic acid, glycocholic acid, or a combination thereof.

15. The process of claim 14, wherein N-lauroyl sarcosinate, taurocholic acid, or glycocholic acid is present in said extracting solution at a concentration of from about 0.16 mM to about 64 mM.

16. The process of claim 14, wherein N-lauroyl sarcosinate, taurocholic acid, or glycocholic acid is present in said extracting solution at a concentration of from about 1.6 mM to about 64 mM.

17. The process of claim 14, wherein N-lauroyl sarcosinate, taurocholic acid, or glycocholic acid is present in said extracting solution at a concentration of from about 16 mM to about 64 mM.

18. The process of claim 1 or 8, wherein said non-denaturing anionic detergent comprises N-lauroyl sarcosinate.

19. The process of claim 1 or 8, wherein said step of extracting is carried out for a period of time of about 12 hours to about 24 hours.

20. The process of claim 1 or 8, wherein said step of extracting is carried out for a period of time of from about 6 hours to about 40 hours.

21. The process of any one of claim 1 or 8, wherein said extracting solution has an alkaline pH.

22. The process of claim 21, wherein said extracting solution further comprises one or more organic or inorganic buffers, wherein an alkaline pH is maintained, and an osmolality of the extracting solution which is hypotonic to the cells in said soft tissue is maintained.

23. The process of claim 1 or 8, wherein said extracting solution is a hypotonic buffered solution at an alkaline pH.

24. The process of claim 1 or 8, further comprising, prior to washing, removing said non-denaturing anionic detergent.

25. The process of claim 1 or 8, wherein said extracting solution comprises one or more endonucleases.

26. The process of claim 25, wherein said one or more endonucleases comprise one or more broad-spectrum endonucleases capable of degrading both deoxyribonucleic acids and ribonucleic acids.

27. The process of claim 26, wherein said one or more broad-spectrum endonucleases comprise one or more recombinant endonucleases.

28. The process of claim 25, wherein said one or more endonucleases are present in said extracting solution at a concentration sufficient to degrade nucleic acids present in said tissue sample.

29. The process of claim 28, wherein said one or more endonucleases are present in said extracting solution at a concentration of from about 20 U/ml tissue to about 400 U/ml tissue.

30. The process of claim 28, wherein said one or more endonucleases are present in said extracting solution at a concentration of about 375 U/ml tissue.

31. The process of claim 1 or 8, wherein said water is USP grade, sterile, endotoxin-free, water.

32. The process of claim 1 or 8, wherein said water replacement agent is selected from the group consisting of polyol family, monoglycerides, monoolein, monolinolein, various short and long chain free fatty acids and their corresponding monoacylglycerol esters, glycerol, adonitol, sorbitol, ribitol, galactitol, D-galactose, 1,3 dihydroxypropanol, ethylene glycol, triethylene glycol, propylene glycol, glucose, sucrose, mannitol, xylitol, meso-erythritol, adipic acid, proline, hydroxyproline and a combination thereof.

33. The process of claim 1 or 8, wherein said water replacement agent comprises glycerol.

34. The process of claim 1 or 8, wherein the storage solution further comprises a second decontaminating agent.

35. The process of claim 34, wherein said first and second decontaminating agents are the same or different and each is selected from the group consisting of alcohol, chlorine dioxide, polyethyleneimine, glycerol, methylparaben, antibiotic, antimicrobial agent, and a combination thereof.

36. The process of claim 35, wherein said first and second decontaminating agents are non-reactive towards said non-denaturing anionic detergent.

37. The process of claim 35, wherein said chlorine dioxide or said methylparaben are present at a concentration in the range of from 0.001% to 0.1% (v:

v) in the storage solution.

38. The process of claim 34, wherein said first and second decontaminating agents are the same or different and each is selected from the group consisting of ethanol, isopropanol, methanol, glycerol, adonitol, sorbitol, ribitol, galactitol, D-galactose, 1,3 dihydroxypropanol, ethylene glycol, triethylene glycol, propylene glycol, glucose, sucrose, mannitol, xylitol, meso-erythritol, adipic acid, proline, hydroxyproline, and a combination thereof.

39. The process of claim 38, wherein said decontaminating agent is present at a concentration in the range of from 20% to 90% (v:

v) in the storage solution.

40. The process of claim 35 or 38, wherein the first and second decontaminating agents are different from one another.

41. The process of claim 35 or 38, wherein the first and second decontaminating agents are the same.

8. A process for preparing a devitalized soft tissue graft for implantation into a mammalian system, comprising:

extracting a soft tissue sample with an extracting solution comprising a non-denaturing anionic detergent to produce an extracted tissue comprising cell lysis remnants,

washing at least some cell lysis remnants from said extracted tissue with water, and

subsequently placing the extracted, washed tissue into a storage solution comprising a water replacement agent and a decontaminating agent to produce said devitalized soft tissue graft,

wherein said devitalized soft tissue graft retains at least one of non-viable cells or cellular elements capable of inducing graft repopulation with an appropriate cell type, and

wherein said process does not include deoxycholic acid or cholic acid.

9. The process of claim 8, wherein said step of extracting is carried out for a time period of from about 6 hours to about 40 hours.

10. The process of claim 9, wherein said time period is from about 16 to about 24 hours.

11. The process of claim 8, wherein said step of extracting is carried out at a temperature of from about 4°

C. to about 42°

C.

12. The process of claim 11, wherein said temperature is from about 15°

C. to about 27°

C.